Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
data highlight that TFDP3 is expressed in breast cancer, that it is a member of the cancer-testis antigen family and that it functions as a regulator in epithelial-mesenchymal transition
TFDP3 was highly expressed in cancer tissues including prostate cancer tissues.TFDP3 was expressed in coordination with E2F1 (zeige E2F1 Proteine) in most prostate cancer tissues.
Data gathered from cell lines, tumorigenicity studies, and primary hepatocellular carcinoma samples demonstrate a negative role of HIF-2alpha (zeige EPAS1 Proteine) in tumors, which is mediated by the TFDP3/E2F1 (zeige E2F1 Proteine) pathway.
Data show that TFDP3 upregulates the expression of autophagy gene LC3B (zeige MAP1LC3B Proteine) and inhibits E2F1 (zeige E2F1 Proteine)-induced apoptosis, and may play an important role in prostate cancer.
DP-4 downregulating E2F-1 (zeige E2F1 Proteine) activity and contributes to a new pRb (zeige RB1 Proteine)-independent mechanism for regulating cell cycle progression.
TFDP3, a novel DP protein, inhibits DNA binding and transactivation by E2F (zeige E2F1 Proteine)
This gene encodes a member of the DP family of transcription factors. These factors heterodimerize with E2F proteins to enhance their DNA-binding activity and promote transcription from E2F target genes. This protein functions as a negative regulator and inhibits the DNA binding and transcriptional activities of E2F factors.
, cancer/testis antigen 30
, hepatocellular carcinoma-associated antigen 661
, transcription factor Dp family member 3
, transcription factor Dp family, member 3